For someone with obesity, the cardiovascular risk reduction from losing 25% of their body weight almost certainly exceeds the risk from a 5 to 10 beat per minute resting heart rate increase
Although several pharmacologic strategies, including sulodexide, metformin, and antithrombin, have shown preliminary promise, clinical evidence remains limited (67)
Research domains include cellular senescence, circadian regulation, and longevity-focused molecular investigations
You dont have to follow a one-size-fits-all plan
Regulatory and Ethical Considerations Current Approval Status (2026) As of 2026, neither cagrilintide nor retatrutide has received FDA approval for obesity treatment or metabolic applications
Quality varies significantly between compounding pharmacies